m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00221)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
CSNK2A2
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Fat mass and obesity-associated protein (FTO) [ERASER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | In bladder cancer, the changes in m6A methylation level mainly appeared at 5' untranslated region (5' UTR) of MALAT1 and NOTCH1 transcripts, and at 3' UTR of Casein kinase II subunit alpha' (CSNK2A2) and ITGA6 transcripts, responding to the overexpression of FTO. SFPQ could influence the FTO-mediated m6A RNA demethylation, eventually affecting the gene expression. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Bladder cancer | ICD-11: 2C94 | ||
Pathway Response | Notch signaling pathway | hsa04330 | ||
Cell Process | Cell proliferation | |||
Cell invasion | ||||
Cell apoptosis | ||||
In-vitro Model | HT-1197 | Recurrent bladder carcinoma | Homo sapiens | CVCL_1291 |
HT-1376 | Bladder carcinoma | Homo sapiens | CVCL_1292 | |
In-vivo Model | BALB/cnu/nu mice (4-5 weeks old) were used for the xenograft experiment. The mice were randomly divided into 2 groups (n = 6 for each group) and injected with 5 × 106 HT-1197 cells in control group or FTO plasmid group, respectively. | |||
RNA demethylase ALKBH5 (ALKBH5) [ERASER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | knockdown of ALKBH5 promoted bladder cancer cell proliferation, migration, invasion, and decreased cisplatin chemosensitivity, ALKBH5 inhibited the progression and sensitized bladder cancer cells to cisplatin through a Casein kinase II subunit alpha' (CSNK2A2)-mediated glycolysis pathway in an m6A-dependent manner. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Bladder cancer | ICD-11: 2C94 | ||
Responsed Drug | Cisplatin | Approved | ||
Pathway Response | Metabolic pathways | hsa01100 | ||
Glycolysis / Gluconeogenesis | hsa00010) | |||
Cell Process | Glycolysis | |||
In-vitro Model | UM-UC-3 | Bladder carcinoma | Homo sapiens | CVCL_1783 |
T24 | Bladder carcinoma | Homo sapiens | CVCL_0554 | |
SV-HUC-1 | Normal | Homo sapiens | CVCL_3798 | |
J82 | Bladder carcinoma | Homo sapiens | CVCL_0359 | |
253J | Bladder carcinoma | Homo sapiens | CVCL_7935 | |
5637 | Bladder carcinoma | Homo sapiens | CVCL_0126 | |
Bladder cancer [ICD-11: 2C94]
In total 2 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | In bladder cancer, the changes in m6A methylation level mainly appeared at 5' untranslated region (5' UTR) of MALAT1 and NOTCH1 transcripts, and at 3' UTR of Casein kinase II subunit alpha' (CSNK2A2) and ITGA6 transcripts, responding to the overexpression of FTO. SFPQ could influence the FTO-mediated m6A RNA demethylation, eventually affecting the gene expression. | |||
Responsed Disease | Bladder cancer [ICD-11: 2C94] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Up regulation | |||
Pathway Response | Notch signaling pathway | hsa04330 | ||
Cell Process | Cell proliferation | |||
Cell invasion | ||||
Cell apoptosis | ||||
In-vitro Model | HT-1197 | Recurrent bladder carcinoma | Homo sapiens | CVCL_1291 |
HT-1376 | Bladder carcinoma | Homo sapiens | CVCL_1292 | |
In-vivo Model | BALB/cnu/nu mice (4-5 weeks old) were used for the xenograft experiment. The mice were randomly divided into 2 groups (n = 6 for each group) and injected with 5 × 106 HT-1197 cells in control group or FTO plasmid group, respectively. | |||
Experiment 2 Reporting the m6A-centered Disease Response | [2] | |||
Response Summary | knockdown of ALKBH5 promoted bladder cancer cell proliferation, migration, invasion, and decreased cisplatin chemosensitivity, ALKBH5 inhibited the progression and sensitized bladder cancer cells to cisplatin through a Casein kinase II subunit alpha' (CSNK2A2)-mediated glycolysis pathway in an m6A-dependent manner. | |||
Responsed Disease | Bladder cancer [ICD-11: 2C94] | |||
Target Regulator | RNA demethylase ALKBH5 (ALKBH5) | ERASER | ||
Target Regulation | Down regulation | |||
Responsed Drug | Cisplatin | Approved | ||
Pathway Response | Metabolic pathways | hsa01100 | ||
Glycolysis / Gluconeogenesis | hsa00010) | |||
Cell Process | Glycolysis | |||
In-vitro Model | UM-UC-3 | Bladder carcinoma | Homo sapiens | CVCL_1783 |
T24 | Bladder carcinoma | Homo sapiens | CVCL_0554 | |
SV-HUC-1 | Normal | Homo sapiens | CVCL_3798 | |
J82 | Bladder carcinoma | Homo sapiens | CVCL_0359 | |
253J | Bladder carcinoma | Homo sapiens | CVCL_7935 | |
5637 | Bladder carcinoma | Homo sapiens | CVCL_0126 | |
Cisplatin
[Approved]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [2] | |||
Response Summary | knockdown of ALKBH5 promoted bladder cancer cell proliferation, migration, invasion, and decreased cisplatin chemosensitivity, ALKBH5 inhibited the progression and sensitized bladder cancer cells to cisplatin through a Casein kinase II subunit alpha' (CSNK2A2)-mediated glycolysis pathway in an m6A-dependent manner. | |||
Target Regulator | RNA demethylase ALKBH5 (ALKBH5) | ERASER | ||
Target Regulation | Down regulation | |||
Responsed Disease | Bladder cancer | ICD-11: 2C94 | ||
Pathway Response | Metabolic pathways | hsa01100 | ||
Glycolysis / Gluconeogenesis | hsa00010) | |||
Cell Process | Glycolysis | |||
In-vitro Model | UM-UC-3 | Bladder carcinoma | Homo sapiens | CVCL_1783 |
T24 | Bladder carcinoma | Homo sapiens | CVCL_0554 | |
SV-HUC-1 | Normal | Homo sapiens | CVCL_3798 | |
J82 | Bladder carcinoma | Homo sapiens | CVCL_0359 | |
253J | Bladder carcinoma | Homo sapiens | CVCL_7935 | |
5637 | Bladder carcinoma | Homo sapiens | CVCL_0126 | |
References